Trial results

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413 on ClinicalTrials.gov · last registry update 2026-08-11

An unusually large phase 2: 285 participants, more than double the 114 typical for the stage. Its estimated completion date, 22 August 2026, has passed with no update to the record. Primary outcome, as filed: Percent Change From Baseline in Body Weight. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P2

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Enrollment

285

Started

2025-05-05

Primary completion

2026-08-22 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Baseline in Body Weight

Conditions studied

Obesity · Overweight · Overweight With One Weight Related Comorbidity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.